{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.9","upperLimit":"58.2","value":"16.7"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"63.2","value":"0"},{"groupId":"OG002","lowerLimit":"1.3","upperLimit":"75.1","value":"25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"description":"The objective response rate is the percent of patients who meet the International Myeloma Working Group Response Criteria for sCR, CR, VGPR, or PR on two consecutive evaluations at least 4 weeks apart among the patients who began study treatment. A 90% binomial confidence interval will be constructed for the overall objective response rate.","dispersionType":"90% Confidence Interval","groups":[{"description":"Ibrutinib 560 mg on Days 1-28,\n\n* Lenalidomide 15 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22\n* Every 28 days","id":"OG000","title":"Dose Level 1 Starting Cohort"},{"description":"* Lenalidomide 15 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22\n* Every 28 days Ibrutinib 560 mg on Days 1-28,\n* Lenalidomide 25 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22\n* Every 28 days","id":"OG001","title":"Dose Level 2"},{"description":"Ibrutinib 840 mg on Days 1-28,\n\n* Lenalidomide 25 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22\n* Every 28 days","id":"OG002","title":"Dose Level 3"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 34 months","title":"Objective Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}